Join to View Full Profile
4301 W Markham St# SlotLittle Rock, AR 72205
Phone+1 501-526-6990
Fax+1 501-526-2273
Dr. Thanendrarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ruhr - University Bochum Faculty of MedicineClass of 2006
Certifications & Licensure
AR State Medical License 2014 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Publications & Presentations
PubMed
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli
Blood Cancer Journal. 2026-03-31 - Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.Toshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, Marah Alzu'bi, Carolina D Schinke
Blood Cancer Journal. 2026-01-06 - Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.Samer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, Aishee Bag, Simon Zhen
Blood Cancer Journal. 2025-11-07
Journal Articles
- Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small AdipocytesBart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology
Abstracts/Posters
- The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple MyelomaSharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Translational Switch of MYC Protein Aliases in Myeloma Tumor CellsSharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Translational Switch of MYC Protein Aliases in Myeloma Tumor CellsSharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
